Charmacy’s Steady Growth in Mid-Year Financials

Charmacy Pharmaceutical Co., Ltd. Class H (HK:2289) has released an update.

Charmacy Pharmaceutical Co., Ltd. has reported a steady growth in their interim financial results for the first half of 2024, with operating revenue increasing by 3.44% and total profit rising by 10.72% compared to the same period in 2023. The net profit attributable to shareholders saw a modest rise of 1.50%, indicating a solid performance despite market challenges.

For further insights into HK:2289 stock, check out TipRanks’ Stock Analysis page.